Skip to main content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes

  • 1Email author,
  • 2,
  • 2,
  • 2,
  • 1,
  • 2,
  • 2,
  • 2 and
  • 2
BMC Cancer201818:1255

https://doi.org/10.1186/s12885-018-5161-4

©  The Author(s). 2018

  • Received: 13 February 2017
  • Accepted: 29 November 2018
  • Published:
Open Peer Review reports

Abstract

Background

The secretion of soluble factors enables communication between tumour cells and the surrounding microenvironment and plays an important role in oncogenesis. Pancreatic ductal adenocarcinoma (PDAC) is characterised by a highly reactive microenvironment, harbouring a variety of cell types, including S100A8/S100A9-expressing monocytes. S100A8/S100A9 proteins regulate the behaviour of cancer cells by inducing pre-metastatic cascades associated with cancer spread. The aim of this study was to examine how S100A8/A9 proteins mediate tumour-stroma crosstalk in PDAC.

Methods

Cytokine profiling of pancreatic cancer cell-derived conditioned media was performed using Bio-Plex Pro 27 Plex Human Cytokine assays. Protein expression and activation of downstream signalling effectors and NF-κB were assessed by western blotting analysis and reporter assays respectively.

Results

Stimulation of cultured pancreatic cancer cells with S100A8 and S100A9 increased the secretion of the pro-inflammatory cytokines IL-8, TNF-α, and FGF. S100A8, but not S100A9 induced PDGF secretion. Conversely, pancreatic cancer cell-derived conditioned media and the individual cytokines, TNF-α and TGF-β induced the expression of S100A8 and S100A9 proteins in the HL-60 monocytic cell line and primary human monocytes, while FGF and IL-8 induced the expression of S100A9 only. S100A8 and S100A9 activated MAPK and NF-κB signalling in pancreatic cancer. This was partially mediated via activation of the receptor of advanced glycosylation end-product (RAGE).

Conclusion

S100A8 and S100A9 proteins induce specific cytokine secretion from PDAC cells, which in turn enhances the expression of S100A8/A9. This paracrine crosstalk could have implications for PDAC invasiveness and metastatic potential.

Keywords

  • Pancreatic Cancer
  • Stroma
  • S100A8
  • S100A9
  • Cytokines
  • Monocytes

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and a leading cause of cancer deaths worldwide [1]. Despite advances in our understanding of the pathophysiology of PDAC, there have been limited improvements in clinical outcome. This is in part due to the presence of a highly reactive stroma that promotes carcinogenesis, confers resistance to conventional therapy [2–5] and increases PDAC aggressiveness [6]. The tumour stroma comprises extracellular matrix and a variety of cell types including cancer-associated fibroblasts, stellate cells, endothelial cells and inflammatory cells such as macrophages and monocytes [7, 8]. The latter secrete the potent chemokines S100A8 and S100A9 which are low molecular proteins of S100 family of EF-hand calcium binding proteins. Both proteins are constitutively expressed in cells of myeloid origin such as monocytes and neutrophils [9]. Once secreted in the extracellular space, S100A8/A9 act as chemo-attractants recruiting further inflammatory cells and creating an inflammatory microenvironment that promotes tumour development [10, 11]. In-vivo and in-vitro experiments have shown a strong link between the levels of S100A8/S100A9 and several disorders such as cystic fibrosis, rheumatoid arthritis, atherosclerosis and cardiovascular disease [11–14]. Secreted S100A8/S100A9 proteins have also been implicated in cancer growth [15, 16] and in the establishment of a favourable environment for metastasis by promoting the migration of monocytes and tumor cells to metastatic sites [17, 18]. This process involves vascular endothelial growth factor-A (VEGF-A) and TGF-ß-SMAD4 signalling pathways and both toll-like receptor-4 (TLR-4) [19], and the receptor for advanced glycation end-products (RAGE) [20]. However little is known about S100A8 and S100A9-mediated cross talk between stromal monocytes and pancreatic cancer cells. In the current study, we show that exposing monocytes to pancreatic tumour cell-derived conditioned media increased the expression of both S100A8 and S100A9. Secreted S100A8/A9 from monocytes, in turn, led to secretion of several cytokines from pancreatic tumour cells. This was mediated by RAGE and was associated with phosphorylation of Erk1/2, p38 kinase and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells pathway (NF-κB).

Methods

MAPK antibodies (phospho-JNK, phospho-Erk1/2 and phospho-p38) were obtained from Cell Signaling Technology. S100A8 and S100A9 antibodies were purchased from Santa Cruz and the Bio-Plex Pro 27 Plex Human Cytokine, Chemokine and Growth Factor Assay was from Bio-Rad Laboratories Ltd., Hercules, CA, USA.

Cell culture

Pancreatic cancer cell lines; CFPAC-1 (ATCC: CRL-1918), Suit-2, BxPC-3 (ATCC: CRL-1687) and Panc-1 (ATCC: CRL-1469) were obtained from ATCC (Rockville, MD) and maintained in a humidified incubator at 37 °C in RPMI-1640 containing 10% FBS, 2 mm l-glutamine, 2500 IU/mL penicillin and 5 μg/mL streptomycin (all from Sigma, Poole, UK). All cell lines were authenticated using short tandem repeat profiling against international reference standards.

Isolation of human monocytes

Blood samples were obtained with written consent from two healthy volunteers under approved protocols at the Royal Liverpool University Hospital. Human monocytes were isolated from peripheral blood mononuclear cells (PBMCs) obtained from buffy coat preparations. Enriched monocyte fractions were isolated by positive selection using CD14-magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer’s instructions. Monocytes were eluted in 5 mL MACS buffer and the purity (> 90%) verified by FACS analysis using anti-CD14 conjugated FITC antibody or isotype control.

Stimulation of human monocytes

Freshly isolated monocytes were plated in 24-well plates in RPMI 1640 media supplemented with 10% FBS and stimulated with tumour cell-conditioned media from Panc-1, Suit-2 or BxPC-3 cell lines. Isolated monocytes were also treated with recombinant human growth factors (TGF-β, VEGF, IL-8 and FGF). After 24 h incubation, cell lysates were prepared using Tris/SDS lysis buffer and subjected to immuno-blotting assays.

Conditioned media preparation

Pancreatic cancer cells were counted and seeded in 6-well plates in RPMI media. After 24 h, cells were washed twice with PBS and incubated in serum free-RPMI and treated with 2 μg/mL of the recombinant proteins S100A8-GST, S100A9-GST or GST and incubated for an additional 24 h at 37 °C. For blocking experiments, cells were incubated with anti-RAGE antibody (R&D, Abingdon, UK) for 1 h prior to addition of recombinant proteins. For neutralising experiments, S100A8-GST and S100A9-GST proteins were incubated with respective neutralising antibodies (anti-S100A8 and anti-S100A9) for 1 h at 37 °C before treating cancer cells in culture. Cell supernatants were collected, centrifuged at 500x g for 5 min, to remove cellular debris, and then filtered through 0.2 μm filter units. Conditioned media were stored in -80 °C freezer until use.

Cytokines profiling assay

A Luminex assay (Bio-Plex Pro 27 Plex Human Cytokine kit) enabling the simultaneous measurement of 27 secreted cytokines in the conditioned media of pancreatic cancer cells was performed. Briefly, serially diluted standards and undiluted conditioned media (50 μL) were added to a microfilter plate containing antibody-coupled beads for each of the 27 analytes and incubated for 60 min with continuous shaking at room temperature. After washing steps, the biotinylated detection antibodies were added for 30 min with shaking. The microfilter plate was washed again, and Streptavidin-PE (50 μL) added and incubation continued at room temperature with shaking (900 rpm for 1 min followed by 300 rpm for 15 min). Assay buffer (125 μL) was added to each well of the microfilter plate before being read on a Bio-Plex 200 machine.

Immunoblotting analysis

Total cell lysates were extraction by re-suspending cells in 100 mm Tris–HCl (pH 6.8) containing 2% w/v SDS and a protease inhibitor cocktail (Complete, Mini, EDTA-free protease inhibitors; Roche Applied Science, UK). Protein samples were quantified using a BCA protein assay kit (Perbio Science Ltd., Cramlington, UK) then subjected to SDS–PAGE. Separated proteins were transferred to hybond nitrocellulose membranes (Amersham Biosciences, Bucks, UK). Membranes were then blocked for 1 h with TBS containing 0.1% Tween-20 (TBS-T) and 5% milk (Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire, UK) and then incubated overnight at 4 °C with antibodies specific for phospho-JNK, phospho-ERK1/2 and phospho-p38 (Cell Signaling Technology, Beverly,CA, USA) diluted 1:1000 in 5% BSA in TBST. The β-actin (clone AC-15, Sigma, Poole, UK) was used at a 1:10,000 dilution. Blots were washed with TBST and incubated for 1 h with horseradish-peroxidase (HRP)-conjugated secondary antibodies diluted 1:4000 in 5% skim milk in TBST. Bound HRP was visualised using the enhanced chemiluminescence kit (PerkinElmer Life Sciences, Bucks, UK).

NF-κB luciferase assay

Pancreatic cancer cells, Panc-1, were trypsinised, counted and transfected using nucleofector and nucleofector solution-R (Amaxa, UK) according to the manufacturer’s instructions. Cells were transfected with 3 μg of NF-κB plasmid or control plasmid from Clontech. 3 μg of GFP plasmid (Amaxa) was also used to monitor transfection efficiency. Cells were immediately removed from cuvettes, transferred into prepared 6-well plates and incubated in a humidified 37 °C/ 5% CO2 incubator. After 24 h of incubation, the cells were washed twice with PBS and incubated in serum free RPMI with or without 10 μg/mL of polymyxin-b, the latter used in order to monitor the stimulatory effect of bacterial LPS. Cells were treated with 2 μg/mL of either S100A8, S100A9, GST recombinant proteins or human TNF-α (50 ng/mL), as a positive control of NF-κB induction, and incubated for an additional 24 h. Luciferase activity was measured according to the Clontech kit recommendations (Clontech, Mountain View, CA, USA).

Statistical analysis

Statistical analyses were performed using student t-test. A p-value less than 0.05 was considered statistically significant.

Results

Cytokine profiling of pancreatic cancer cell-derived conditioned media

Previously, we reported the presence of both S100A8-positive and S100A9-positive stromal monocytes in the tumour microenvironment of pancreatic and colorectal tumours [15]. Moreover, we observed that the number of S100A8-positive monocytes was significantly lower in tumours which lacked Smad-4 [21], suggesting a paracrine interaction between tumour cells and the monocytic stromal compartment. To decipher crosstalk between PDAC tumour cells and S100A8- and S100A9-expressing monocytes, we examined whether stimulation of Panc-1 pancreatic cancer cells with recombinant S100A8-GST or S100A9-GST fusion proteins altered their cytokine secretion, compared to stimulation with the control protein, GST. The profile of cytokines secreted from unstimulated Panc-1 cells is shown in Additional file 1: Table S1. Following incubation of Panc-1 cells with either S100A8-GST or S100A9-GST recombinant proteins, significant increases in IL-8, TNF-α and FGF were observed (Fig. 1a-c). Incubation of recombinant S100A8-GST and S100A9-GST proteins with respective anti-S100A8 and anti-S100A9 neutralising antibodies impaired their stimulatory effects, indicating that the stimulation was specific to S100A8 and S100A9. Moreover, incubation of Panc-1 cells with an anti-RAGE-blocking antibody prior to the addition of recombinant proteins reversed the stimulatory effects of S100A8 and S100A9 on TNF-α, and FGF, but not IL-8. Finally, the level of PDGF was increased after treatment of Panc-1 cells with recombinant S100A8 protein, but not recombinant S100A9 protein, and this increase was blocked by anti-S100A8– but not anti-RAGE– neutralising antibodies (Fig. 1d). Taken together, our data suggest that S100A8 and S100A9 have both overlapping and distinct effects on cytokine secretion, with those effects only partly mediated by the RAGE receptor.
Fig. 1
Fig. 1

Effects of S100A8 and S100A9 proteins on the secretion of selected cytokines from Panc-1 cells. Conditioned media were collected from untreated cells or cells treated for 24 h with S100A8-GST (A8-GST), S100A9-GST (A9-GST), or treated with recombinant proteins which have been pre-incubated for 1 h with neutralising antibodies (A8-GST + αA8, A9-GST + αA9) or GST protein only. Conditioned media were also collected from cancer cells pre-treated for 1 h with anti-RAGE blocking antibody and then stimulated with recombinant proteins (A8-GST + αRAGE, A9-GST + αRAGE). The cytokine levels were measured using the Bio-Plex Pro 27 Plex Human Cytokine kit, and expressed relative to untreated control levels. Experiments were performed in duplicate three times and error bars denote standard error. * = P values < 0.05

Conditioned media from pancreatic cancer cells induced S100A8/A9 expression in monocytes

Having observed that S100A8 and S100A9 proteins altered the secreted cytokine profile from Panc-1 cells, we next asked whether secreted factors from Panc-1 and other PDAC cell lines could influence the expression of S100A8/A9 in monocytes. Treatment of the monocytic cell line HL-60 with conditioned media from CFPAC-1, BxPc-3, Panc-1 and Suit-2 led to a pronounced increase in the expression of both S100A8 and S100A9 (Fig. 2a). This effect was not observed when HL-60 cells were incubated with mouse embryonic fibroblast (MEF)-derived conditioned media or control unconditioned media (Fig. 2a).
Fig. 2
Fig. 2

Effects of individual cytokines and secreted factors from pancreatic cancer cells on expression of S100A8 and S100A9 proteins in monocytes. A] Western blot analysis of S100A8 and S100A9 expression in HL-60 cells after treatment with conditioned media (CM) derived from the indicated pancreatic cancer cell lines; CFPAC-1, BxPC-3, Panc-1 and Suit-2, B, C and D] Western blot analysis of S100A8 and S100A9 expression in HL-60 cells following incubation with increasing concentrations of FGF, IL-8, TGF-β and TNF-α respectively. β-actin was used as a loading control

Cytokines induce expression of S100A8/A9 in monocytes

Having established that pancreatic cancer cells secrete factors that induce the expression of monocytic S100A8 and S100A9 (Fig. 2a) and that the S100 proteins themselves induced the secretion of FGF, IL-8, and TNF-α from pancreatic cancer cells (Fig. 1), we questioned whether FGF, IL-8 and TNF-α might contribute to the induction of monocytic S100A8 and S100A9 expression in a paracrine fashion. TGF-β was also examined, as it was previously shown to induce expression of S100A8/A9 in lung Mac 1+-myeloid cells [17]. Neither FGF nor IL-8 altered S100A8 in HL-60 cells (Fig. 2b and C), and only a very modest increase was observed for S100A9 expression after addition of either cytokine (Fig. 2b and c). Both S100A8 and S100A9 expression were increased in HL-60 cells (Fig. 2d) after the addition of recombinant human cytokines TGF-β and TNF-α, although a dose-dependent effect was not observed.

We next determined whether PDAC cell-conditioned media or cytokines could induce S100A8 and S100A9 expression in primary human monocytes. Conditioned media from Panc-1, Suit-2 and BxPc3 cancer cell lines caused increased expression of S100A8 and S100A9 proteins in primary human monocytes (Fig. 3). FGF and IL-8 treatment resulted in a strong induction of S100A9, but not S100A8 expression in primary human monocytes, while TGF-β and TNF-α both induced S100A8 and S100A9 expression in primary monocytes (Figs. 3).
Fig. 3
Fig. 3

Effects of individual cytokines and secreted factors from pancreatic cancer cells on expression of S100A8 and S100A9 proteins in primary human monocytes. Western blot analysis of S100A8 and S100A9 expression in primary human monocytes after incubation with 10 ng/mL of the following cytokines FGF, IL-8, TGF-β and TNF-α, and after treatment with CM from Panc-1, Suit-2 and BxPC-3 cell lines

S100A8/A9 activate downstream signalling pathways

We next investigated downstream mediators of S100A8 and S100A9 signalling in pancreatic cancer cells, including phospho-MAPK proteins (Fig. 4a) and NF-κB (Fig. 4b). Panc-1 cells treated with S100A8 and S100A9 proteins for one hour showed higher than control levels of the phospho-MAPK proteins, phospho-p38 and phospho-Erk-1/2 (Fig. 4a). These effects were respectively abrogated by pre-treatment of proteins with anti-S100A8 or anti-S100A9 antibodies. Moreover, this observation was RAGE-dependent, since blockage of RAGE receptor using anti-RAGE antibody was accompanied by lower levels of p-p38 and p-Erk-1/2 (Fig. 4a). The addition of S100A8/A9 recombinant proteins did not alter the phosphorylation status of SAPK/JNK. The effects of treatment of Panc-1 cells with S100A8 and S100A9 on the basal levels of these MAPK proteins was not examined. In this system, we conclude that treatment with S100A8 and S100A9 proteins is accompanied by higher levels of phosphorylated p38 and Erk1/2 than untreated controls, and that the RAGE receptor is required for this effect.
Fig. 4
Fig. 4

Signalling downstream of S100A8 and S100A9. A] Panc-1 cells were treated with [2 μg/mL] of recombinant A8-GST, A9-GST, A8-GST + αA8, A9-GST + αA9, A8-GST + αRAGE and A9-GST + αRAGE for 60 min and probed by Western blotting for the indicated phosphoproteins. β-actin served as a loading control. B] Panc-1 cells were transfected with NF-κB and control reporters [2 μg of DNA] and stimulated with recombinant A8-GST, A9-GST or GST [2 μg/mL] for 24 h. Cells treated with TNF-α [10 ng/mL] served as a positive control for NF-κB induction. For blocking conditions, cells were treated with anti-RAGE blocking antibody for 1 h prior to stimulation. S100A8-GST and S100A9-GST were incubated with anti-S100A8 and anti-S100A9 neutralising antibodies for 1 h before addition to cancer cell cultures. Luciferase activity was plotted as the mean ± SEM of three independent experiments, each performed in triplicate. Error bars represent standard error (* P < 0.05)

Ligand binding to RAGE receptor triggers intracellular signalling and stimulates a number of transcription factors including NF-κB [22]. Transient transfection of Panc-1 cells with an NF-κB reporter plasmid followed by incubation with recombinant S100A8 and S100A9 proteins for 24 h produced a significant activation of NF-κB luciferase activity compared to mock transfected, transfected but untreated or GST treated controls (Fig. 4b). The observed increase in luciferase activity was blocked by the relevant S100 antibodies. Moreover, it was exclusively related to the action of S100A8/A9 proteins and not to bacterial lipopolysaccharides (LPS) because addition of 10 μg/mL polymyxin-b, which is a potent inhibitor of LPS, gave similar results (Additional file 2: Figure S1). Pre-incubation with RAGE blocking antibody abolished the S100A8 and S100A9-induced NF-κB activation, indicating that S100A8 and S100A9 proteins activated NF-κB via the RAGE receptor. As expected, TNF-α which served as a positive control in this experiment, significantly promoted NF-κB luciferase activity.

Discussion

The complex interaction between pancreatic tumour cells and surrounding immune cells is increasingly understood to be vital in sustaining tumour growth and progression [23, 24]. Stromal cells potentiate tumour development through the secretion of a complex network of autocrine and paracrine factors including cytokines, proteases and growth factors [25, 26].

We previously showed that the stromal compartment of colorectal and pancreatic cancers contain CD14+ monocytic cells expressing S100A8 and S100A9 proteins [21]. Moreover, we observed that Smad4-negative pancreatic and colorectal tumours contain fewer stromal S100A8-positive monocytes than their Smad4-positive counterparts [21, 27], suggesting a regulated relationship between cancer cells and surrounding monocytic cells. No such relationship was observed for S100A9-positive monocytes, indicating a distinction between S100A8- and S100A9-expressing tumour-associated monocytes. We also reported that exogenously added S100A8 and S100A9 proteins enhanced the migration and proliferation of colorectal and pancreatic cancer cells in culture [15]. In the current study, we found that S100A8 and S100A9 proteins influenced cytokine secretion from pancreatic cancer cells in overlapping but also distinct ways. Whilst both recombinant S100A8-GST and S100A9-GST proteins induced increased secretion of the pro-inflammatory cytokines IL-8 and TNF-α and the growth factor FGF, only S100A8-GST induced PDGF secretion. This again highlights a distinction between these two closely related S100 proteins.

S100A8/A9 are reported to stimulate cells through binding to the cellular receptor RAGE, a primary receptor which, when activated, is associated with amplified inflammatory conditions and tumour progression [27]. Here we found that the secretion of TNF-α and FGF was mediated via the RAGE receptor, whilst the RAGE receptor was not required for IL-8 and PDGF secretion. S100A8/A9 signaling from receptors other than the RAGE receptor has previously been reported, including the binding of S100A8/A9 to Toll-like receptor-4 receptor and the newly discovered EMMPRIN receptor that exclusively binds to S100A9 but not S100A8 [28, 29].

Previous studies have elucidated a role for S100A8/A9 in preparing a pre-metastatic niche in distant organs through activation of serum amyloid A3 and toll-like receptor 4 (TLR4) [17, 19]. For patients with pancreatic cancer, release of S100A8/A9 proteins from myeloid cells increases CD33+CD14−HLA-DR− myeloid-derived suppressor cells [30]. Our observation that media conditioned from pancreatic cancer cells, as well as the individual cytokines TGF-β and TNF-α, induced the expression of S100A8 and S100A9 proteins in HL-60 cells and primary monocytes supports the concept of a paracrine feedback loop, whereby cancer cells induce monocytic S100A8/A9 expression through cytokine secretion and the S100 proteins in turn induce cytokine secretion. Secretion of TGF-β by pancreatic cancer cells induces extra-cellular matrix (ECM) formation and enhances fibrosis [31]. Both TGF-β and TNF-α have been associated with increased cancer cell proliferation and motility. Additionally, both TGF-β and TNF-α participate in the creation of inflammatory environments that enhance tumorigenesis and immunosuppressive activity blocking the host’s anti-tumour response [32]. Induction of S100A8 and S100A9 expression in response to primary lung tumor cell-derived soluble factors VEGF-A, TGF-β and TNF-α in myeloid cells prior to tumor metastasis has been reported [17].

Binding of S100A8 and S100A9 to RAGE receptor activates a cascade of downstream signalling pathways [27]. We report here a RAGE-dependent increase in levels of phosphor-Erk1/Erk2 and phospho-p38 phosphorylation following S100A8 and S100A9 treatment of pancreatic cancer cells, although we did not examine the basal levels of these proteins. Furthermore, the S100 proteins activated the NF-κB pathway through RAGE. Activation of the MAPK/NF-κB signaling axis is known to enhance tumor growth, survival, and migration [33]. Moreover, NF-κB activation is also critical in establishing an inflammatory microenvironment which in turn sets the stage for cancer progression [33].

In summary, our data suggest the existence of paracrine feedback loop between stroma-associated S100A8/A9-secreting cells and pancreatic tumour cells. This feedback loop may affect tumour progression. Hence, targeting S100A8/A9 represents a potential therapeutic option to curtail the aggressive nature of pancreatic cancer.

Abbreviations

FGF: 

Fibroblast growth factor

GST: 

Glutathione S-transferase

IL-8: 

Interleukin-8

LPS: 

Lipopolysaccharides

NF-κB: 

Nuclear factor kappa-light-chain-enhancer of activated B cells

PDAC: 

Pancreatic ductal adenocarcinoma

RAGE: 

receptor of advanced glycosylation end-product

TGF-β: 

Transforming growth factor- beta.

TLR-4: 

Toll-like receptor-4

TNF-α: 

Tumour necrosis factor-alpha

VEGF: 

Vascular endothelial growth factor

Declarations

Acknowledgements

The authors would like to acknowledge King Abdullah International Medical Research Center (KAIMRC) for their financial support to cover the publication fees.

Funding

This work was financially supported by Pancreatic Cancer Research Fund [PCRF] and the NIHR Liverpool Pancreas Biomedical Research Unit (PBRU). The funding body has no role in study design, data collection and analysis, interpretation of data; in the writing of the manuscript.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

TN carried out the experiment and writing of the manuscript. AE and AS, participated in data acquisition and manuscript writing. LB, participated in data acquisition and interpretation. SA and LO helped in data analysis and drafted the manuscript. WG and JN participated in study design and critically corrected the manuscript. EC participated in study design and writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all volunteers according to our institutional guidelines. The study was approved by the National Research Ethnics (NRES) Service Committee North WestGreater Manchester North 08/H1011/36.

Consent for publication

Not applicable.

Competing interests

The authors do not have any conflicts of interest associated with this manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, P. O. Box 9515, Jeddah, 21423, Saudi Arabia
(2)
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, UK

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMedView ArticleGoogle Scholar
  2. Neesse A, Algul H, Tuveson D, Gress T. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476–84.PubMedView ArticleGoogle Scholar
  3. Erkan M, Reiser-Erkan C, Michalski CW, Kong B, Esposito I, Fiess H, et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med. 2012;12(3):288–303.PubMedView ArticleGoogle Scholar
  4. Korc M. Pancreatic cancer-associated stroma production. Am J Surg. 2007;194(Suppl 4):S84–6.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011;71(3):1019–28.PubMedView ArticleGoogle Scholar
  6. Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, et al. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest. 2016;126(11):4140–56.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56(8):1134–52.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Tjomsland V, Niklasson L, Sandstrom P, Borch K, Druid H, Bratthall C, et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol. 2011;2011:212810.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Gross SR, Sin CG, Barraclough R, Rudland PS. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 2014;71(9):1551–79.PubMedView ArticleGoogle Scholar
  10. Leach ST, Day AS. S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Rev Clin Immunol. 2006;2(3):471–80.PubMedView ArticleGoogle Scholar
  11. Passey RJ, Xu K, Hume DA, Geczy CL. S100A8: emerging functions and regulation. J Leukoc Biol. 1999;66(4):549–56.PubMedView ArticleGoogle Scholar
  12. Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol. 2010;88(1):41–9.PubMedView ArticleGoogle Scholar
  13. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, Wienbrandt AR, et al. S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling. Basic Res Cardiol. 2012;107(2):250.PubMedView ArticleGoogle Scholar
  14. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011;123(11):1216–26.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, et al. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics. 2007;7(11):1929–40.PubMedView ArticleGoogle Scholar
  16. Ichikawa M, Williams R, Wang L, Voql T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011;9(2):133–48.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8(12):1369–75.PubMedView ArticleGoogle Scholar
  18. Yan HH, Pickup M, Panq Y, Gorska AE, Li Z, Chytil A, et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010;70(15):6139–49.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008;10(11):1349–55.PubMedView ArticleGoogle Scholar
  20. Narumi K, Miyakawa R, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T, et al. Proinflammatory proteins S100A8/S100A9 activate NK cells via interaction with RAGE. J Immunol. 2015;194(11):5539–48.PubMedView ArticleGoogle Scholar
  21. Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, et al. Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis. 2010;31(9):1541–51.PubMedView ArticleGoogle Scholar
  22. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal. 2009;7:12.PubMedPubMed CentralView ArticleGoogle Scholar
  23. Feig C, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266–76.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Habtezion A, Edderkaoui M, Pandol SJ. Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett. 2016;381(1):211–6.PubMedView ArticleGoogle Scholar
  25. Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 2014;345(2):157–63.PubMedView ArticleGoogle Scholar
  26. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27(1):11–8.PubMedView ArticleGoogle Scholar
  27. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008;205(2):275–85.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Ehrchen JM, Sunderkotter C, Foell D, Volq T, Roth J. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–66.PubMedView ArticleGoogle Scholar
  29. Hibino T, Sakaquchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, et al. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res. 2013;73(1):172–83.PubMedView ArticleGoogle Scholar
  30. Basso D, Fogar P, Plebani M. The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: implications for pancreatic cancer-driven immunosuppression. Oncoimmunology. 2013;2(6):e24441.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterol. 2005;128(4):907–21.View ArticleGoogle Scholar
  32. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.PubMedView ArticleGoogle Scholar
  33. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us